Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?